PTPN1 and hypertrophic cardiomyopathy: Although a clear connection of this therapeutic intervention with hypertrophic cardiomyopathy or malignancy has not been clearly established, patients’ genotyping is mandatory as specific mutations in PTPN1 associated to leukemia or mutations in genes linked to the development of hypertrophic cardiomyopathy (e.g., RIT1) [reviewed in (68, 69)] are among the exclusion criteria.